Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial

AbstractObjectivesContrast-induced acute kidney injury (CI-AKI) is a serious complication in patients undergoing diagnostic cardiac angiography or percutaneous coronary intervention. We aimed to evaluate the preventive effects of left ventricular end-diastolic pressure (LVEDP)-guided hydration for the prevention of CI-AKI in patients with chronic kidney disease undergoing cardiac catheterization.MethodsThis prospective randomized single-blind clinical trial enrolled 114 eligible patients with an estimated glomerular filtration rate (eGFR) of 15  
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research

Related Links:

Hyperuricaemia refers to an abnormally high concentration of uric acid in serum [1], typically defined as>7  mg/dL (416 μmol/L) in men and>6  mg/dL in women [1]. Mean serum uric acid has increased progressively over the last century in many populations and the prevalence of hyperuricemia increases with age and is higher in men than premenopausal women [1], as oestrogen increases urate excretion by the kidneys. Hyperuricaemia is usually discussed in the context of gout, but it is increasingly recognised that serum uric acid values>5.0  mg/dL (men) or 4.5 mg/dL (postmenopausal women) are clinically rele...
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Of Interest Source Type: blogs
We thank Yildirim and colleagues for their interest in our study [1]. Direct oral anticoagulants (DOACs) are increasingly used in patients with chronic kidney disease (CKD). Recent guidelines even recommend apixaban as reasonable for patients with atrial fibrillation (AF) and end-stage CKD [2]. Yildirim et al. asked for details regarding our patients with CKD and bleeding events. This information was presented in Table 3 [1]. To summarize, two patients with renal disease had a bleeding event: one on apixaban (5  mg b.i.d.), and the other on rivaroxaban (10 mg/day).
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research
ConclusionsAbout 5% of community-dwelling older adults had an eGFR  
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
In this report, we retrospectively compared the clinical benefits of two PDE3 inhibitors, milrinone and olprinone, to determine which better controls the progression of CHF. A total of 288 hospitalized patients who received PDE3 inhibitors [(milrinone;n = 77 and olprinone;n = 211, respectively)] for CHF were retrospectively enrolled. The primary endpoint was defined as having a major adverse cardiovascular and cerebrovascular event (MACCE) or cardiac death by day 60. Kaplan–Meier curves and multivariate Cox proportional models were used to compare the outcomes f or patients treated with mi...
Source: Heart and Vessels - Category: Cardiology Source Type: research
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Vincent M. Brandenburg, Alexander Schuh, Rafael KramannAccelerated and premature cardiovascular calcification is a hallmark of patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD). The presence and the amount of cardiovascular calcification are among the driving forces of increased morbidity and mortality in renal patients. Cardiovascular calcification occurs at different sites, including the cardiac valves—a location that is of particular importance for both the patient and the treating phy...
Source: Advances in Chronic Kidney Disease - Category: Urology & Nephrology Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Gupta R, Sharma KK, Soni S, Gupta N, Khedar RS Abstract Background: Hypertension is highly prevalent in India but frequency of resistant hypertension has not been well studied. Methods: We performed a registry-based study at a single center in patients with primary diagnosis of hypertension (n=3073). Details of co-morbidities, medications and blood pressure (BP) control were obtained. Patients with coronary heart disease, cerebrovascular disease and chronic kidney disease were excluded. Resistant hypertension was defined as uncontrolled hypertension (BP ≥140/90) with use of 3 drugs of which one was ...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Abstract Background: Cardiac dysfunction and cardiovascular (CV) events are prevalent among patients with chronic kidney disease (CKD) without overt obstructive coronary artery disease (CAD) but the mechanisms remain poorly understood. Coronary microvascular dysfunction (CMD) has been proposed as a link between abnormal renal function and impairment of cardiac function and CV events. We sought to investigate the relationships between CKD, CMD, cardiac dysfunction and adverse CV outcomes. Methods: Patients undergoing cardiac stress positron emission tomography (PET), echocardiogram and renal function ascertainment ...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
More News: Angiography | Angioplasty | Cardiac Catheterization | Cardiology | Chloride | Chronic Kidney Disease | Clinical Trials | Coronary Angioplasty | Dialysis | Diets | Eyes | Heart | Heart Disease | Hemodialysis | Nutrition | Percutaneous Coronary Intervention | Sodium | Sodium Chloride | Study | Urology & Nephrology